Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.25% | -56.05% | -44.96% | -41.99% | -77.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.37% | -61.18% | -58.55% | -17.97% | -72.67% |
| Operating Income | 30.37% | 61.18% | 58.55% | 17.97% | 72.67% |
| Income Before Tax | 27.49% | 83.77% | 227.54% | 19.20% | 72.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.49% | 83.77% | 227.54% | 19.20% | 72.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.49% | 83.77% | 227.54% | 19.20% | 72.61% |
| EBIT | 30.37% | 61.18% | 58.55% | 17.97% | 72.67% |
| EBITDA | 30.41% | 61.19% | 58.63% | 17.76% | 72.91% |
| EPS Basic | 58.26% | 78.88% | 164.97% | 59.56% | 83.49% |
| Normalized Basic EPS | 58.28% | -199.34% | 164.96% | 59.57% | 83.52% |
| EPS Diluted | 58.26% | 79.05% | 158.82% | 59.56% | 83.49% |
| Normalized Diluted EPS | 58.28% | -199.34% | 163.46% | 59.57% | 83.52% |
| Average Basic Shares Outstanding | 73.06% | -22.93% | 96.22% | 99.89% | 65.80% |
| Average Diluted Shares Outstanding | 73.06% | -22.93% | 100.77% | 99.89% | 65.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |